{"url_path":"/sec/pbm/10-k/2026/item-8","section_key":"item-8","section_title":"Item 8 FINANCIAL INFORMATION","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1985062/0001213900-26-070607-index.html","accession_number":"0001213900-26-070607","cik":"0001985062","ticker":"PBM","issuer_name":"PSYENCE BIOMEDICAL LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1985062/0001213900-26-070607-index.html","primary_entity_key":"0001985062","primary_entity_name":"PSYENCE BIOMEDICAL LTD."},"word_count":142,"has_tables":true,"body_markdown":"** **\n\nITEM 8. FINANCIAL INFORMATION\n\n \n\n**A.****Consolidated Statements and Other Financial Information**\n\n \n\nFinancial Statements\n\n \n\nOur consolidated financial statements begin on\npage F-1.\n\n** **\n\nDividend Policy\n\n \n\nPsyence has not paid any cash dividends on its\nshares to date and does not intend to pay cash dividends in the foreseeable future. The payment of cash dividends in the future will be\ndependent upon the Company’s revenue and earnings, if any, capital requirements and general financial condition. The payment of\nany cash dividends is within the discretion of the Board. Further, our ability to declare dividends may be limited by the terms of financing\nor other agreements entered into by us or our subsidiaries from time to time.\n\n** **\n\nB. Significant Changes\n\n \n\nExcept as disclosed elsewhere in this Report,\nno other significant changes to our financial condition have occurred since the date of the financial statements contained herein.\n\n \n\n70"}